Payment overview · 2025
General Payments
$1,280.37
79 reported records · 17 companies
Healthcare provider profile · identity verified
Gary G. Williams, MD
Allopathic & Osteopathic Physicians|Family Medicine · SALINA, KS · NPI 1306801626
Verified facts
What the public records show
CMS Open Payments records show Gary G. Williams, MD received $1,280.37 in general payments during 2025 across 79 reported records.
PFIZER INC. accounted for 24.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 30 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Arexvy, Eliquis, Mounjaro, Ozempic, Shingrix.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported AREXVY as an associated drug or biological on 47563 records involving 28786 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Arexvy by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 110 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 293 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $313.52 | 24.5% | 21 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $306.29 | 23.9% | 19 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $151.16 | 11.8% | 9 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $76.93 | 6.0% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $74.92 | 5.8% | 4 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $64.08 | 5.0% | 4 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $51.64 | 4.0% | 3 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $45.34 | 3.5% | 2 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $38.02 | 3.0% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $33.35 | 2.6% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $30.34 | 2.4% | 2 | 2025 |
| VERTEX PHARMACEUTICALS INCORPORATED | Unresolved — no canonical attribution shown | $20.42 | 1.6% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $19.38 | 1.5% | 1 | 2025 |
| Xeris Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $16.44 | 1.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $15.75 | 1.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $13.86 | 1.1% | 1 | 2025 |
| Phathom Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $8.93 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,280.37 | 79 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $306.29 | 19 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $291.28 | 18 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $178.32 | 14 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $135.20 | 7 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $119.86 | 9 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $100.45 | 5 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $98.88 | 5 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $89.89 | 4 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $74.92 | 4 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $64.08 | 4 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $58.46 | 5 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $51.64 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $51.64 | 3 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $46.94 | 3 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $46.94 | 3 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $45.34 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $45.20 | 4 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $38.02 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $30.34 | 2 | 2025 |
Source payment records
|
|||||
| PENMENVY Normalized: penmenvy |
Biological | GlaxoSmithKline, LLC. | $29.99 | 2 | 2025 |
Source payment records
|
|||||
| JOURNAVX Normalized: journavx |
Drug | VERTEX PHARMACEUTICALS INCORPORATED | $20.42 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $19.38 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $19.14 | 1 | 2025 |
Source payment records
|
|||||
| RECORLEV Normalized: recorlev |
Drug | Xeris Pharmaceuticals, Inc. | $16.44 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.07 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM G7 GSS (161) Normalized: dexcom g7 gss 161 |
Medical Supply | Dexcom, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| DEXCOM STELO GLUCOSE BIOSENSOR Normalized: dexcom stelo glucose biosensor |
Not specified | Dexcom, Inc. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.21 | 1 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $13.86 | 1 | 2025 |
Source payment records
|
|||||
| VOQUEZNA Normalized: voquezna |
Drug | Phathom Pharmaceuticals, Inc. | $8.93 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| AREXVY arexvy |
2025 | Arexvy | 2024 | 36 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 293 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 110 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 35 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | AREXVY open payments reported associated product |
CMS Open Payments — General Payments 47563 supporting records · 28786 recipient NPIs · example record 1190332445 |
Arexvy · 2024 Exact normalized brand match · 1 Part D row |
36 | 36 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
35 | 23 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
110 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
293 | 41 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 794 | 175 |
| Levothyroxine Sodium | Levothyroxine Sodium | 556 | 109 |
| Losartan Potassium | Losartan Potassium | 554 | 128 |
| Metoprolol Succinate | Metoprolol Succinate | 497 | 112 |
| Omeprazole | Omeprazole | 482 | 120 |
| Amlodipine Besylate | Amlodipine Besylate | 416 | 98 |
| Gabapentin | Gabapentin | 393 | 74 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 378 | 65 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 371 | 100 |
| Potassium Chloride | Potassium Chloride | 345 | 78 |
| Meloxicam | Meloxicam | 313 | 81 |
| Furosemide | Furosemide | 304 | 68 |
| Metformin Hcl | Metformin Hcl | 303 | 66 |
| Simvastatin | Simvastatin | 299 | 75 |
| Eliquis | Apixaban | 293 | 41 |
| Warfarin Sodium | Warfarin Sodium | 254 | 25 |
| Pantoprazole Sodium | Pantoprazole Sodium | 230 | 43 |
| Lisinopril | Lisinopril | 219 | 58 |
| Tamsulosin Hcl | Tamsulosin Hcl | 209 | 52 |
| Metoprolol Tartrate | Metoprolol Tartrate | 201 | 45 |
| Hydrochlorothiazide | Hydrochlorothiazide | 180 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 166 | 40 |
| Clopidogrel | Clopidogrel Bisulfate | 154 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 137 | 32 |
| Fluoxetine Hcl | Fluoxetine Hcl | 132 | 29 |
| Tramadol Hcl | Tramadol Hcl | 120 | 36 |
| Allopurinol | Allopurinol | 110 | 26 |
| Citalopram Hbr | Citalopram Hydrobromide | 110 | 25 |
| Mounjaro | Tirzepatide | 110 | 17 |
| Alprazolam | Alprazolam | 104 | 22 |
| Duloxetine Hcl | Duloxetine Hcl | 100 | 16 |
| Montelukast Sodium | Montelukast Sodium | 96 | 21 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 35 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 89 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 88 | 20 |
| Prednisone | Prednisone | 86 | 38 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 86 | 20 |
| Atenolol | Atenolol | 85 | 18 |
| Sertraline Hcl | Sertraline Hcl | 84 | 16 |
| Azithromycin | Azithromycin | 79 | 70 |
| Cefdinir | Cefdinir | 76 | 56 |
| Donepezil Hcl | Donepezil Hcl | 76 | 16 |
| Spironolactone | Spironolactone | 76 | 18 |
| Amitriptyline Hcl | Amitriptyline Hcl | 74 | 18 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 71 | 12 |
| Methylprednisolone | Methylprednisolone | 69 | 55 |
| Trazodone Hcl | Trazodone Hcl | 69 | 17 |
| Zolpidem Tartrate | Zolpidem Tartrate | 69 | 20 |
| Klor-Con M20 | Potassium Chloride | 66 | 19 |
| Glipizide Er | Glipizide | 64 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 61 | 16 |
| Estradiol | Estradiol | 60 | 15 |
| Digoxin | Digoxin | 59 | 11 |
| Ezetimibe | Ezetimibe | 58 | 12 |
| Famotidine | Famotidine | 58 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 56 | suppressed |
| Memantine Hcl | Memantine Hcl | 53 | suppressed |
| Celecoxib | Celecoxib | 52 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 52 | suppressed |
| Carvedilol | Carvedilol | 49 | 13 |
| Finasteride | Finasteride | 46 | 12 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 45 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 45 | suppressed |
| Bupropion Xl | Bupropion Hcl | 43 | 12 |
| Pravastatin Sodium | Pravastatin Sodium | 43 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 42 | 11 |
| Primidone | Primidone | 41 | suppressed |
| Premarin | Estrogens, Conjugated | 39 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 37 | 12 |
| Arexvy | Rsvpref3 Antigen/As01e/Pf | 36 | 36 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 36 | 26 |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 35 | 23 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 34 | 24 |
| Nystatin | Nystatin | 34 | 19 |
| Morphine Sulfate | Morphine Sulfate | 33 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 32 | suppressed |
| Clonazepam | Clonazepam | 31 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 30 | suppressed |
| Etodolac | Etodolac | 29 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 29 | suppressed |
| Pregabalin | Pregabalin | 29 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Novolog Flexpen | Insulin Aspart | 28 | suppressed |
| Ozempic | Semaglutide | 28 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 28 | suppressed |
| Valsartan | Valsartan | 28 | suppressed |
| Repatha Sureclick | Evolocumab | 27 | suppressed |
| Topiramate | Topiramate | 27 | suppressed |
| Gemfibrozil | Gemfibrozil | 26 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 26 | suppressed |
| Naproxen | Naproxen | 25 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Trulicity | Dulaglutide | 25 | suppressed |
| Acyclovir | Acyclovir | 24 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 24 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 17 |
| Nitroglycerin | Nitroglycerin | 23 | 19 |
| Synthroid | Levothyroxine Sodium | 23 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 22 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 22 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 14 |
| Solifenacin Succinate | Solifenacin Succinate | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | 18 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 21 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 21 | suppressed |
| Glipizide | Glipizide | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 20 | 15 |
| Cephalexin | Cephalexin | 19 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 19 | 14 |
| Sumatriptan Succinate | Sumatriptan Succinate | 19 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 19 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lansoprazole | Lansoprazole | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 16 |
| Arnuity Ellipta | Fluticasone Furoate | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 15 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 15 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lorazepam | Lorazepam | 14 | suppressed |
| Ibuprofen | Ibuprofen | 13 | suppressed |
| Xarelto | Rivaroxaban | 13 | suppressed |
| Betaxolol Hcl | Betaxolol Hcl | 12 | suppressed |
| Buprenorphine | Buprenorphine | 12 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 12 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 12 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Lovastatin | Lovastatin | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 12 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 12 | suppressed |
| Xtampza Er | Oxycodone Myristate | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,280.37 · 79 records | PFIZER INC. | ABRYSVO, AIRSUPRA, AREXVY, BREZTRI, CAPLYTA, COMIRNATY, CRYSVITA, DEXCOM G7 GSS (161), DEXCOM STELO GLUCOSE BIOSENSOR, ELIQUIS, GEMTESA, JOURNAVX, LEQVIO, MOUNJARO, NURTEC ODT, Ozempic, PENMENVY, PREVNAR 20, QULIPTA, RECORLEV, REPATHA, Rybelsus, SHINGRIX, Tymlos, UBRELVY, VOQUEZNA, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Arexvy play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error